Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Interest & Investment Income (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Interest & Investment Income for 9 consecutive years, with -$4.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income rose 29.81% to -$4.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$24.2 million, a 32.96% decrease, with the full-year FY2025 number at -$24.2 million, down 32.96% from a year prior.
  • Interest & Investment Income was -$4.8 million for Q4 2025 at Akebia Therapeutics, down from -$4.7 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of -$1.4 million in Q3 2023 to a low of -$7.8 million in Q1 2025.
  • A 5-year average of -$4.2 million and a median of -$4.8 million in 2021 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: skyrocketed 69.16% in 2023, then crashed 384.98% in 2024.
  • Akebia Therapeutics' Interest & Investment Income stood at -$5.1 million in 2021, then surged by 67.81% to -$1.6 million in 2022, then increased by 13.33% to -$1.4 million in 2023, then crashed by 384.98% to -$6.9 million in 2024, then increased by 29.81% to -$4.8 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Interest & Investment Income are -$4.8 million (Q4 2025), -$4.7 million (Q3 2025), and -$6.8 million (Q2 2025).